In addition to treating patients with bleeding and clotting disorders in our comprehensive care clinic, the dedicated physicians, pharmacists and research staff of the UCHTC constantly pursue groundbreaking new treatments for these rare disorders.
Our on-site laboratory is responsible for the storage and analysis of thousands of blood samples, serving the UCHTC clinic as well as national studies that are on the cutting edge of detecting, defining and evaluating bleeding and clotting disorders. Drs. Marilyn Manco-Johnson and Jorge DiPaola manage lab studies, Linda Jacobson, Lisa Villalobos-Menuey, Chris Bombardier and a staff of student researchers. To learn more about the UCHTC Laboratory, click HERE.
In addition to lab research, the UCHTC coordinates several clinical studies that evaluate the effectiveness of improved drugs on clotting in people with bleeding disorders, seeking to improve patient care, long and short-term joint health, Factor VIII inhibitor immune tolerance therapies and patient healthcare costs in association with access to necessary treatments. The team also collects information about risk factors for thrombosis, features of blood clots, treatment and prevention of blood clots and patient long-term outcomes. Taylor Blades, the Clinical Research Manager, manages all aspects of all these studies and coordinates study participation. To learn more about Clinical Research, click HERE.
Our current studies include two national multi-center studies and several national studies sponsored by the Centers for Disease Control and the Hemophilia and Thrombosis Research Society. As part of our commitment to raising national awareness for people with bleeding and clotting disorders, the center has developed several databases that are used to house the information collected for these studies, enabling analysis of treatment progress. If you would like to learn more about any one of the many studies at the UCHTC, please contact our Clinical Research Manager, Taylor Blades at Taylor.Blades@ucdenver.edu, or click HERE.